Ublituximab A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

被引：2

作者：

Boldrini, Vinicius Oliveira ^{[1
,2
]}

Mader, Simone ^{[3
,4
]}

Kuempfel, Tania ^{[3
,4
]}

Meinl, Edgar ^{[3
,4
]}

机构：

[1] Univ Estadual Campinas, Dept Neurol, Neuroimaging Lab, Campinas, SP, Brazil

[2] Univ Estadual Campinas, Brazilian Inst Neurosci & Neurotechnol BRAINN, Campinas, SP, Brazil

[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Inst Clin Neuroimmunol, Munich, Germany

[4] Ludwig Maximilians Univ Munchen, Med Fac, Biomed Ctr BMC, Martinsried, Germany

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2023年 / 75卷

关键词：

TERIFLUNOMIDE; OCRELIZUMAB;

D O I：

10.1016/j.msard.2023.104733

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Ublituximab, an intravenous glycoengineered chimeric anti-CD20 IgG1 monoclonal antibody (mAb), is a new FDA-approved treatment for relapsing forms of Multiple Sclerosis (MS). Reassembling the other three anti-CD20 mAbs already in use for MS (rituximab, ocrelizumab and ofatumumab), ublituximab leads to depletion of B cells but spars long-lived plasma cells. Here, we discuss the main findings obtained during the phase 3 clinical trials (ULTIMATE I and II) for ubli-tuximab versus teriflunomide. The current emergence and approval of new anti-CD20 mAbs with different dose regimens, routes of application, glycoengineering and mechanisms of action may contribute to different clinical outcomes.

引用

页数：4

共 19 条

[1]

Alvarez E, 2022, MULT SCLER J, V28, P67

[2] Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study [J].

Bar-Or, Amit ;

Wiendl, Heinz ;

Montalban, Xavier ;

Alvarez, Enrique ;

Davydovskaya, Maria ;

Delgado, Silvia R. ;

Evdoshenko, Evgeniy P. ;

Giedraitiene, Natasa ;

Gross-Paju, Katrin ;

Haldre, Sulev ;

Herrman, Craig E. ;

Izquierdo, Guillermo ;

Karelis, Guntis ;

Leutmezer, Fritz ;

Mares, Miroslav ;

Meca-Lallana, Jose E. ;

Mickeviciene, Dalia ;

Nicholas, Jacqueline ;

Robertson, Derrick S. ;

Sazonov, Denis, V ;

Sharlin, Kenneth ;

Sundaram, Bharathy ;

Totolyan, Natalia ;

Vachova, Marta ;

Valis, Martin ;

Bagger, Morten ;

Haring, Dieter A. ;

Ludwig, Inga ;

Willi, Roman ;

Zalesak, Martin ;

Su, Wendy ;

Merschhemke, Martin ;

Fox, Edward J. .

MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (06) :910-924

[3] Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies [J].

Dunn, Nicky ;

Juto, Alexander ;

Ryner, Malin ;

Manouchehrinia, Ali ;

Piccoli, Luca ;

Fink, Katharina ;

Piehl, Fredrik ;

Fogdell-Hahn, Anna .

MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (09) :1224-1233

[4] Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II [J].

Gaertner, Jutta ;

Hauser, Stephen L. ;

Bar-Or, Amit ;

Montalban, Xavier ;

Cohen, Jeffrey A. ;

Cross, Anne H. ;

Deiva, Kumaran ;

Ganjgahi, Habib ;

Haering, Dieter A. ;

Li, Bingbing ;

Pingili, Ratnakar ;

Ramanathan, Krishnan ;

Su, Wendy ;

Willi, Roman ;

Kieseier, Bernd ;

Kappos, Ludwig .

MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) :1562-1575

[5] Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis [J].

Hauser, S. L. ;

Bar-Or, A. ;

Comi, G. ;

Giovannoni, G. ;

Hartung, H. -P. ;

Hemmer, B. ;

Lublin, F. ;

Montalban, X. ;

Rammohan, K. W. ;

Selmaj, K. ;

Traboulsee, A. ;

Wolinsky, J. S. ;

Arnold, D. L. ;

Klingelschmitt, G. ;

Masterman, D. ;

Fontoura, P. ;

Belachew, S. ;

Chin, P. ;

Mairon, N. ;

Garren, H. ;

Kappos, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) :221-234

[6] B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis [J].

Hauser, Stephen L. ;

Waubant, Emmanuelle ;

Arnold, Douglas L. ;

Vollmer, Timothy ;

Antel, Jack ;

Fox, Robert J. ;

Bar-Or, Amit ;

Panzara, Michael ;

Sarkar, Neena ;

Agarwal, Sunil ;

Langer-Gould, Annette ;

Smith, Craig H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (07) :676-688

[7] Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis [J].

Hauser, Stephen L. ;

Bar-Or, Amit ;

Weber, Martin S. ;

Kletzl, Heidemarie ;

Guenther, Andreas ;

Manfrini, Marianna ;

Model, Fabian ;

Mercier, Francois ;

Petry, Claire ;

Wing, Qing ;

Koendgen, Harold ;

Smith, Terence ;

Kappos, Ludwig .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (02)

[8] Ofatumumab versus Teriflunomide in Multiple Sclerosis [J].

Hauser, Stephen L. ;

Bar-Or, Amit ;

Cohen, Jeffrey A. ;

Comi, Giancarlo ;

Correale, Jorge ;

Coyle, Patricia K. ;

Cross, Anne H. ;

de Seze, Jerome ;

Leppert, David ;

Montalban, Xavier ;

Selmaj, Krzysztof ;

Wiendl, Heinz ;

Kerloeguen, Cecile ;

Willi, Roman ;

Li, Bingbing ;

Kakarieka, Algirdas ;

Tomic, Davorka ;

Goodyear, Alexandra ;

Pingili, Ratnakar ;

Haring, Dieter A. ;

Ramanathan, Krishnan ;

Merschhemke, Martin ;

Kappos, Ludwig .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :546-557

[9]

Ho S., 2023, NEUROL-NEUROIMMUNOL

[10]

Kappos L., 2020, JAMA NEUROL

← 1 2 →